<?xml version='1.0' encoding='utf-8'?>
<document id="25639891"><sentence text="Mechanism-based inactivation of CYP450 enzymes: a case study of lapatinib."><entity charOffset="64-73" id="DDI-PubMed.25639891.s1.e0" text="lapatinib" /></sentence><sentence text="Mechanism-based inactivation (MBI) of CYP450 enzymes is a unique form of inhibition in which the enzymatic machinery of the victim is responsible for generation of the reactive metabolite" /><sentence text=" This precondition sets up a time-dependency for the inactivation process, a hallmark feature that characterizes all MBI" /><sentence text=" Yet, MBI itself is a complex biochemical phenomenon that operates in different modes, namely, covalent binding to apoprotein, covalent binding of the porphyrin group and also complexation of the catalytic iron"><entity charOffset="151-160" id="DDI-PubMed.25639891.s4.e0" text="porphyrin" /><entity charOffset="206-210" id="DDI-PubMed.25639891.s4.e1" text="iron" /><pair ddi="false" e1="DDI-PubMed.25639891.s4.e0" e2="DDI-PubMed.25639891.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25639891.s4.e0" e2="DDI-PubMed.25639891.s4.e1" /></sentence><sentence text=" Using lapatinib as a recent example of toxicological interest, we present an example of a mixed-function MBI that can confound clinical drug-drug interactions manifestation"><entity charOffset="7-16" id="DDI-PubMed.25639891.s5.e0" text="lapatinib" /></sentence><sentence text=" Lapatinib exhibits both covalent binding to the apoprotein and formation of a metabolite-intermediate complex in an enzyme-selective manner (CYP3A4 versus CYP3A5), each with different reactive metabolites"><entity charOffset="1-10" id="DDI-PubMed.25639891.s6.e0" text="Lapatinib" /></sentence><sentence text=" The clinical implication of this effect is also contingent upon genetic polymorphisms of the enzyme involved as well as the co-administration of other substrates, inhibitors or inducers, culminating in drug-drug interactions" /><sentence text=" This understanding recapitulates the importance of applying isoform-specific mechanistic investigations to develop customized strategies to manage such outcomes" /><sentence text=" " /></document>